We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Lonza, Forty Seven Manufacturing Agreement

News   Oct 13, 2016

 
Lonza, Forty Seven Manufacturing Agreement
 
 
Advertisement
 

RELATED ARTICLES

Mutated Form of SARS-CoV-2 is Dominant, But Doesn't Make Patients Sicker, Study Says

News

In a collaborative research study, scientists show that a mutated version of SARS-CoV-2 has become the predominant form across the globe. Whilst the variant competes with the original strain, clinical data suggests that it does not make individuals sicker.

READ MORE

Controlled Human Infection Models for SARS-CoV-2 Vaccine Development

News

Infecting some volunteers with COVID-19 may provide valuable insights for future rounds of vaccine testing, but would require very strict controls, argues a group of infectious disease experts in the New England Journal of Medicine.

READ MORE

Peptide Combo Could Help Reduce Damage Caused By SARS-CoV-2

News

Two peptides once combined, work together to penetrate cells' membranes in order to dampen an acute inflammatory response. In this first ex vivo study, the peptide reduced collagen degradation. The researchers say the peptide could alleviate some of the worst damage caused by acute inflammatory responses.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE